Answers are grounded in this paper and cite their sources.
Mitochondrial dysfunction is a fundamental driver of the onset and progression of atherosclerosis, as it disrupts cell metabolic homeostasis and fuels lipid accumulation and chronic inflammatory activation. However, therapeutic strategies that effectively restore mitochondrial function remain limited, and mitochondria delivery system capable of selectively targeting atherosclerotic plaques are still lacking. Here, we engineered a mitochondria-loaded vesicular system with inflamed endothelium-targeting capability (Mito@euMVs-Vt) to re-establish mitochondrial homeostasis in foam macrophages. Mito@euMVs-Vt markedly improved mitochondrial architecture and bioenergetic function, thereby alleviating lipid droplet accumulation, cellular senescence, and inflammatory activation that collectively drive atherosclerotic pathology. In an atherosclerotic mouse model, Mito@euMVs-Vt significantly reduced aortic plaque burden, improved vascular compliance, and enhanced fibrous-cap collagen deposition without eliciting systemic toxicity. By integrating selective targeting of inflamed endothelium with functional mitochondrial transfer, this work highlights a promising and mechanistically grounded therapeutic strategy for atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: